Lyell Immunopharma, Inc. (LYEL)
Recent Filing Index
| Form | Filed | Qtr End | F_Period | 8K: Earnings Release |
|---|---|---|---|---|
| 10-QLatest | Q2-2026 | 8-K (2026-08-06) · 99.1 | ||
| 10-Q | Q1-2026 | 8-K (2026-05-06) · 99.1 | ||
| 10-KLatest | FY-2025 | 8-K (2026-03-12) · 99.1 | ||
| 10-Q | Q3-2025 | 8-K (2025-11-12) · 99.1 | ||
| 10-Q | Q2-2025 | 8-K (2025-08-12) · 99.1 | ||
| 10-Q | Q1-2025 | 8-K (2025-05-13) · 99.1 | ||
| 10-K | FY-2024 | 8-K (2025-03-11) · 99.1 | ||
| 10-Q | Q3-2024 | 8-K (2024-11-07) · 99.1 | ||
| 10-Q | Q2-2024 | 8-K (2024-08-07) · 99.1 | ||
| 10-Q | Q1-2024 | 8-K (2024-05-06) · 99.1 | ||
| 10-K | FY-2023 | 8-K (2024-02-28) | ||
| 10-Q | Q3-2023 | 8-K (2023-11-07) · 99.1 |
Filing Summary
| Report Name | Notes | Fiscal Period (Annual) | Fiscal Period (Quarter) |
|---|---|---|
| Cover | ||
| Audit Information | — |
|
| Statements | ||
| Consolidated Balance Sheets | ||
| Consolidated Balance Sheets (P) | ||
| Consolidated Statements of Operations and Comprehensive Loss | ||
| Consolidated Statements of Operations and Comprehensive Loss (P) | ||
| Consolidated Statements of Stockholders Equity | ||
| Consolidated Statements of Stockholders Equity (P) | ||
| Consolidated Statements of Cash Flows | ||
| Consolidated Statements of Convertible Preferred Stock and Stockholders Equity (deficit) | — |
|
| Consolidated Statements of Convertible Preferred Stock and Stockholders Equity (deficit) (P) | — |
|
| Notes | ||
| Accrued Liabilities and Other Current Liabilities | — |
|
| Acquisitions | — |
|
| Asset Acquisitions and Contingent Consideration | — |
|
| Basis of Presentation and Significant Accounting Policies | — |
|
| Cash Equivalents and Marketable Securities | ||
| Commitments and Contingencies | ||
| Contingent Consideration Payable and Royalty Payments | — |
|
| Convertible Preferred Stock | — |
|
| Cybersecurity Risk Management and Strategy Disclosure | — |
|
| Employee Benefit Plan | — |
|
| Fair Value Measurements | ||
| Impairment of Long-lived Assets | — |
|
| Income Taxes | — |
|
| Insider Trading Arrangements | ||
| Insider Trading Policies and Procedures | — |
|
| Leases | ||
| License, Collaboration and Success Payment Agreements | ||
| License, Collaboration, and Success Payment Agreements | — |
|
| Net Loss Per Share | ||
| Organization | ||
| Other Investments | ||
| Pay Vs Performance Disclosure | ||
| Property and Equipment, Net | — |
|
| Related-party Transactions | ||
| Segment | ||
| Stock-based Compensation | ||
| Stockholders Equity | ||
| Subsequent Events | ||
| Summary of Significant Accounting Policies | — |
|
| Workforce Reduction | — |
|